Medicis Pharmaceutical to Present at Thomas Weisel Partners Healthcare Conference

SCOTTSDALE, Ariz.--March 29, 2001--Medicis Pharmaceutical Corporation (NYSE:MRX) today announced that a live webcast of its presentation scheduled for Monday, April 2, 2001, at 10 a.m. P.D.T. (1 p.m. E.D.T.), may be accessed via the Internet.

Medicis is scheduled to present at the Thomas Weisel Partners Healthcare Tailwinds 2001 Conference - Specialty Pharmaceuticals, Drug Delivery and Healthcare Technology - at the San Francisco Ritz Carlton Hotel.

The webcast will be available via a link on the Medicis corporate web site at http://www.medicis.com/ir/index.html. This link will allow any visitor to the web site to access the Medicis presentation. An archive of the webcast will be available on the Medicis corporate web site at the same URL address for two days following the conference.

Medicis is the leading independent pharmaceutical company in the United States focusing primarily on the treatment of dermatological conditions. Medicis develops and markets leading products for major segments within dermatology including acne, fungal infections, psoriasis, eczema, rosacea, seborrheic dermatitis, head lice and cosmesis (improvement in the texture and appearance of skin). Primary products include the prescription brands DYNACIN(R) (minocycline HCl), TRIAZ(R) (benzoyl peroxide), LUSTRA(R) (hydroquinone), LOPROX(R) (ciclopirox), OVIDE(R) (malathion), PLEXION(TM) (sodium sulfacetamide/sulfur), LIDEX(R) (fluocinonide), SYNALAR(R) (fluocinolone acetonide), TOPICORT(R) (desoximetasone), NOVACET(R) (sodium sulfacetamide/sulfur) and A/T/S(R) (erythromycin); the over-the-counter brand ESOTERICA(R); and BUPHENYL(TM) (sodium phenylbutyrate), a prescription product indicated in the treatment of Urea Cycle Disorder.

Except for historical information, this news release contains certain forward-looking statements that involve risks and uncertainties which may cause actual results to differ materially from the statements made, including the Company's dependence on sales of key products, uncertainty of future financial results and fluctuations in operating results, dependence on the Company's acquisition strategy, new product introductions and other risks described from time to time in the Company's SEC filings. These forward-looking statements represent the judgment of the Company, as of the date of this release, and Medicis disclaims any intent or obligation to update these forward-looking statements.

NOTE: Full prescribing information for any Medicis prescription product is available by contacting the Company.

Contacts:
Medicis Pharmaceutical Corporation, Scottsdale
Libby Ivy, 602/808-3854